$263.64
-0.40%Cencora, Inc. sources and distributes pharmaceutical products. Its U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The company also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; and pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. The company's International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; and distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers and hospitals primarily in Europe. This segment also provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
EVice President & President of International Business Group
EVice President and President of U.S. Pharmaceuticals & Animal Health
Executive Chairman
Compensation
$5,975,070
Executive Vice President & Chief Financial Officer
Compensation
$2,403,452
Executive Vice President & Chief Human Resources Officer
Compensation
$1,719,839
Executive Vice President & Chief Legal Officer
Compensation
$1,968,477
Executive Vice President and Chief Data & Information Officer
President, Chief Executive Officer & Director
Compensation
$3,253,065
Senior Vice President & Chief Compliance Officer
Senior Vice President, Chief Accounting Officer & Corporate Controller
Senior Vice President, Head of Investor Relations & Treasury
During the last 12 months, insiders have purchased $1.07M and sold $41.55M worth of COR shares, resulting in $40.48M of net selling activity.
4.0K
1.07M
0
0.00
+1.1M
+$1.07M
0
0.00
24.3K
8.50M
-8.5M
-$8.50M
0
0.00
48.5K
14.69M
-14.7M
-$14.69M
0
0.00
62.7K
18.36M
-18.4M
-$18.36M
Durcan Dermot Mark
Director
$1.07M
Collis Steven H
Director, Officer: Executive Chairman
$21.85M
Mauch Robert P.
Director, Officer: President & Ceo
$14.79M
Battaglia Silvana
Officer: Executive Vice President
$1.79M
Campbell Elizabeth S
Officer: Executive Vice President
$1.74M
Krikorian Lazarus
Officer: Svp & Chief Accounting Officer
$1.38M
Strong bearish signal with $40.48M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
COR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | January 22, 2026 | March 05, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | January 23, 2025 | March 06, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | January 29, 2024 | March 12, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | January 27, 2023 | March 09, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | January 27, 2022 | March 10, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | January 28, 2021 | March 11, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | January 24, 2020 | March 05, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | January 18, 2019 | February 28, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | January 19, 2018 | March 01, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | January 20, 2017 | March 02, 2017 | 2017 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.